JSKN003 + envafolimab

**JSKN003 + envafolimab** is a fixed-dose combination drug comprising JSKN003, an anti-HER2 biparatopic antibody-drug conjugate (ADC), and envafolimab, a humanized anti-PD-L1 monoclonal antibody fusion protein. JSKN003 is engineered to bind HER2 receptors on tumor cells and deliver a cytotoxic topoisomerase I inhibitor via cellular endocytosis, leveraging enhanced serum stability and a strong bystander effect for more potent anti-tumor efficacy[3][5][7]. Envafolimab is a subcutaneously injectable PD-L1 inhibitor composed of a humanized single-domain antibody fused to an IgG1 Fc fragment, blocking the PD-1/PD-L1 pathway to augment anti-tumor immune response. It is noted for its convenience of subcutaneous administration, high water solubility, rapid tumor penetration, and minimized infusion reactions[2][4][7]. The innovative co-formulation (JSKN033) is developed to synergize ADC therapy with immune checkpoint inhibition, aiming to improve efficacy and safety, and is presently in phase I/II clinical trials for advanced or metastatic solid tumors[7].

Other names

JSKN033JSKN-033JSKN 033